THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
DIETARY SUPPLEMENT & NUTRACEUTICAL PROFILE CODE: [SUP-17] ID: TIP-MED-000641

Myo-Inositol & D-Chiro-Inositol (40:1 Physiological Ratio)

Active Ingredient / Scientific Identity: Myo-Inositol + D-Chiro-Inositol • Class: Clinical Nutrition & Nutraceutical Science • Carbocyclic Polyol Intracellular Insulin & FSH Second-Messenger Precursors

⚖️ Compare 579 Drugs
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Myo-Inositol & D-Chiro-Inositol (40:1 Physiological Ratio) ([SUP-17] | ID: TIP-MED-000641) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/sup-17-myo-inositol-d-chiro-inositol/
Generic / Entity NameMyo-Inositol & D-Chiro-Inositol (40:1 Physiological Ratio) ([SUP-17])
Verified Indian Brands / RefFSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
Pharmacological ClassClinical Nutrition & Nutraceutical Science • Carbocyclic Polyol Intracellular Insulin & FS
Available Dosage FormsPhysiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-
Regulatory ClassificationFSSAI Nutraceutical / Food for Special Dietary Use Ingredient.
Key Warning & Review DateTHE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin
Reviewed: 2026-11-10
Safety Matrix:⚖️ Regulatory Framework: FSSAI Nutraceutical / Food for Special Dietary Use I✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Myo-Inositol & D-Chiro-Inositol (40:1 Physiological Ratio) (TIP-MED-000641, Reference Code [SUP-17]) is classified under Dietary Supplements & Nutraceuticals (FSSAI / ICMR-NIN) as a Clinical Nutrition & Nutraceutical Science • Carbocyclic Polyol Intracellular Insulin & FSH Second-Messenger Precursors. Within the Indian regulatory and compendial framework, it is governed under FSSAI Nutraceutical / Food for Special Dietary Use Ingredient..

Verified Indian Market Examples / Compendial Status:
FSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
Nutritional & Regulatory Reference: Physiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol (40:1 plasma physiological ratio) twice daily before meals. (FSSAI Nutraceutical / Food for Special Dietary Use Ingredient.).
Dosage Forms & Available Strengths:
Physiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol (40:1 plasma physiological ratio) twice daily before meals.
Routes: Oral Nutritional Supplementation

Clinical Nutrition, ICMR-NIN RDA & FSSAI Nutraceutical Profile

Nutrient / Nutraceutical Identity:
Myo-Inositol + D-Chiro-Inositol
Category:
Carbocyclic Polyol Intracellular Insulin & FSH Second-Messenger Precursors
Natural Dietary Sources (Indian Context):
Whole grains, beans, citrus fruits, and cantaloupe; endogenous synthesis from glucose-6-phosphate

ICMR-NIN 2024 Recommended Dietary Allowance (RDA) & Tolerable Upper Intake Limit (UL): Physiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol (40:1 plasma physiological ratio) twice daily before meals.

Deficiency Clinical Syndromes vs Chronic Excess / Hypervitaminosis Risks: THE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin-sensitive and over-converts Myo-Inositol into D-Chiro-Inositol -> therefore administering high-dose standalone D-Chiro-Inositol (>600–1,200 mg/day without Myo-Inositol) depletes intra-ovarian Myo-Inositol, impairs FSH signalling, and worsens oocyte quality! Always maintain the 40:1 Myo:D-Chiro ratio. Doses >12 g/day cause osmotic diarrhoea and flatulence.

Drug–Nutrient Chelation & Timing Interactions: Additive insulin-sensitising effect when combined with Metformin (beneficial synergy in PCOS, though GI tolerability and glucose should be monitored if combined with sulfonylureas or insulin).

FSSAI Health Supplement vs Therapeutic Drug Distinction: FSSAI Nutraceutical / Food for Special Dietary Use Ingredient.

3. Mechanism of Action & Pharmacodynamics

Incorporated into membrane phosphatidylinositol phosphates (PIP2), generating Inositol Triphosphate (IP3) and Inositol Phosphoglycan (IPG) second messengers: Myo-Inositol mediates FSH signalling in ovarian granulosa cells and GLUT4 glucose uptake, while D-Chiro-Inositol (synthesized from Myo-Inositol via insulin-dependent epimerase) mediates glycogen synthesis.

4. Therapeutic Indications & Evidence-Supported Uses

  • Physiological & Biochemical Role: Incorporated into membrane phosphatidylinositol phosphates (PIP2), generating Inositol Triphosphate (IP3) and Inositol Phosphoglycan (IPG) second messengers: Myo-Inositol mediates FSH signalling in ovarian granulosa cells and GLUT4 glucose uptake, while D-Chiro-Inositol (synthesized from Myo-Inositol via insulin-dependent epimerase) mediates glycogen synthesis.
  • Dietary Sources: Whole grains, beans, citrus fruits, and cantaloupe; endogenous synthesis from glucose-6-phosphate
  • ICMR-NIN RDA & Upper Limits: Physiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol (40:1 plasma physiological ratio) twice daily before meals.

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Physiological Supplemental Regimen in PCOS Metabolic/Ovulatory Support: 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol (40:1 plasma physiological ratio) twice daily before meals.

Administration & Meal Timing: Additive insulin-sensitising effect when combined with Metformin (beneficial synergy in PCOS, though GI tolerability and glucose should be monitored if combined with sulfonylureas or insulin).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Salt-form and meal-timing dependent gastrointestinal absorption; see bioavailability and drug-nutrient chelation notes (Additive insulin-sensitising effect when combined with Metformin (beneficial synergy in PCOS, though GI tolerability and glucose should be monitored if combined with sulfonylureas or insulin).).
Metabolism & Biotransformation:
Incorporated into cellular coenzyme pools, metalloproteins, or membrane phospholipids.
Elimination & Renal Adjustment:
Caution with magnesium, potassium, calcium, vitamin D, and high-dose vitamin C/collagen (oxalate) in Chronic Kidney Disease.
Hepatic Impairment Considerations:
Caution with fat-soluble vitamins and concentrated lipophilic extracts in hepatobiliary disease.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Supratherapeutic megadosing above the ICMR-NIN Tolerable Upper Intake Level (UL) without medical indication
  • THE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin-sensitive and over-converts Myo-Inositol into D-Chiro-Inositol -> therefore administering high-dose standalone D-Chiro-Inositol (>600–1,200 mg/day without Myo-Inositol) depletes intra-ovarian Myo-Inositol, impairs FSH signalling, and worsens oocyte quality! Always maintain the 40:1 Myo:D-Chiro ratio. Doses >12 g/day cause osmotic diarrhoea and flatulence.

Key Clinical Precautions: THE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin-sensitive and over-converts Myo-Inositol into D-Chiro-Inositol -> therefore administering high-dose standalone D-Chiro-Inositol (>600–1,200 mg/day without Myo-Inositol) depletes intra-ovarian Myo-Inositol, impairs FSH signalling, and worsens oocyte quality! Always maintain the 40:1 Myo:D-Chiro ratio. Doses >12 g/day cause osmotic diarrhoea and flatulence.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • THE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin-sensitive and over-converts Myo-Inositol into D-Chiro-Inositol -> therefore administering high-dose standalone D-Chiro-Inositol (>600–1,200 mg/day without Myo-Inositol) depletes intra-ovarian Myo-Inositol, impairs FSH signalling, and worsens oocyte quality! Always maintain the 40:1 Myo:D-Chiro ratio. Doses >12 g/day cause osmotic diarrhoea and flatulence.
Serious / Dose-Limiting Adverse Effects:
  • THE 'D-CHIRO-INOSITOL PARADOX': While peripheral skeletal muscle becomes insulin-resistant in PCOS, the ovary remains insulin-sensitive and over-converts Myo-Inositol into D-Chiro-Inositol -> therefore administering high-dose standalone D-Chiro-Inositol (>600–1,200 mg/day without Myo-Inositol) depletes intra-ovarian Myo-Inositol, impairs FSH signalling, and worsens oocyte quality! Always maintain the 40:1 Myo:D-Chiro ratio. Doses >12 g/day cause osmotic diarrhoea and flatulence.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Additive insulin-sensitising effect when combined with Metformin (beneficial synergy in PCOS, though GI tolerability and glucose should be monitored if combined with sulfonylureas or insulin).

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Verify whether the patient requires physiological nutritional maintenance (<=1 RDA under FSSAI) or high-dose therapeutic deficiency correction (Schedule H/medical supervision), and check for multi-supplement stacking.

Pharmacist Patient Counselling Points:

  • Additive insulin-sensitising effect when combined with Metformin (beneficial synergy in PCOS, though GI tolerability and glucose should be monitored if combined with sulfonylureas or insulin).
  • Check all multivitamin and wellness labels to avoid accidentally doubling up on fat-soluble vitamins (A, D, E, K), iron, or zinc.
  • Health supplements support normal physiological nutrition and are NOT intended to diagnose, treat, cure, or prevent disease under Section 22 of the FSS Act, 2006.

Storage, Stability & Dispensing Safeguards: Store in a cool, dry place below 25°C away from moisture and direct sunlight; verify FSSAI License Number and Veg/Non-Veg symbol on packaging.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: ICMR-NIN (National Institute of Nutrition) Nutrient Requirements and Recommended Dietary Allowances (RDA) for Indians (2020/2024); FSSAI (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022.

Official Verification Portals: ICMR-National Institute of Nutrition (NIN) — Dietary Guidelines & Nutrient Requirements for Indians • FSSAI — Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/sup-17-myo-inositol-d-chiro-inositol/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.